Literature DB >> 15701832

Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression.

Eliana Perissinotto1, Giuliana Cavalloni, Francesco Leone, Valentina Fonsato, Stefania Mitola, Giovanni Grignani, Nadia Surrenti, Dario Sangiolo, Federico Bussolino, Wanda Piacibello, Massimo Aglietta.   

Abstract

Despite intensive chemotherapy and surgery treatment, lung and bone metastasis develop in about 30% of patients with osteosarcoma. Mechanisms for this preferential metastatic behavior are largely unknown. We investigated the role of the chemokine receptor 4 (CXCR4)/stromal cell-derived factor 1 (SDF-1) system to drive the homing of osteosarcoma cells. We analyzed the expression of the CXCR4 and SDF-1 proteins on several osteosarcoma cell lines and the effects of SDF-1 on migration, adhesion, and proliferation of these cancer cells. In vitro assays showed that the migration of osteosarcoma cells expressing CXCR4 receptor follows an SDF-1 gradient and that their adhesion to endothelial and bone marrow stromal cells is promoted by SDF-1 treatment. Moreover, the production of matrix metalloproteinase-9 is increased after SDF-1 exposure. We finally proved in a mouse model our hypothesis of the CXCR4/SDF-1 axis involvement in the metastatic process of osteosarcoma cells. Development of lung metastasis after injection of osteosarcoma cells was prevented by the administration of a CXCR4 inhibitor, the T134 peptide. These data show a possible explanation for the preferential osteosarcoma metastatic development into the lung, where SDF-1 concentration is high, and suggest that molecular strategies aimed at inhibiting the CXCR4/SDF-1 pathway, such as small-molecule inhibitors or anti-CXCR4 antibodies, might prevent the dissemination of osteosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701832

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

1.  Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures.

Authors:  David Zagzag; Mine Esencay; Olga Mendez; Herman Yee; Iva Smirnova; Yuanyuan Huang; Luis Chiriboga; Eugene Lukyanov; Mengling Liu; Elizabeth W Newcomb
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

2.  Bone morphogenetic protein 9 overexpression reduces osteosarcoma cell migration and invasion.

Authors:  Zilan Lv; Dandan Yang; Jie Li; Min Hu; Min Luo; Xiaoqin Zhan; Peipei Song; Chen Liu; Huili Bai; Baolin Li; Yang Yang; Yingying Chen; Qiong Shi; Yaguang Weng
Journal:  Mol Cells       Date:  2013-06-25       Impact factor: 5.034

3.  Targeted silencing of CXCR4 inhibits epithelial-mesenchymal transition in oral squamous cell carcinoma.

Authors:  Yuansheng Duan; Shu Zhang; Longlong Wang; Xuan Zhou; Qinghua He; Su Liu; Kai Yue; Xudong Wang
Journal:  Oncol Lett       Date:  2016-07-11       Impact factor: 2.967

4.  Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts.

Authors:  Krithi Rao-Bindal; Chethan K Rao; Ling Yu; Eugenie S Kleinerman
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 5.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

6.  SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer.

Authors:  Bijan Khademi; Mahboobeh Razmkhah; Nasrollah Erfani; Marjan Gharagozloo; Abbas Ghaderi
Journal:  Pathol Oncol Res       Date:  2008-04-02       Impact factor: 3.201

7.  SDF-1alpha G801A polymorphism in Southern Iranian patients with colorectal and gastric cancers.

Authors:  Mahboobeh Razmkhah; Abbas Ghaderi
Journal:  Indian J Gastroenterol       Date:  2012-12-16

8.  Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times.

Authors:  Gayathri T Selvarajah; Jolle Kirpensteijn; Monique E van Wolferen; Nagesha A S Rao; Hille Fieten; Jan A Mol
Journal:  Mol Cancer       Date:  2009-09-07       Impact factor: 27.401

9.  Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Authors:  Ymera Pignochino; Giovanni Grignani; Giuliana Cavalloni; Manuela Motta; Marta Tapparo; Stefania Bruno; Alessia Bottos; Loretta Gammaitoni; Giorgia Migliardi; Giovanni Camussi; Marco Alberghini; Bruno Torchio; Stefano Ferrari; Federico Bussolino; Franca Fagioli; Piero Picci; Massimo Aglietta
Journal:  Mol Cancer       Date:  2009-12-10       Impact factor: 27.401

10.  CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression.

Authors:  Xiaojuan Sun; Lei Wei; Qian Chen; Richard M Terek
Journal:  Mol Cancer       Date:  2010-01-26       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.